Generate Insights for Natural History Studies and HEOR

Life sciences companies are always looking to contextualize outcomes, particularly around their drugs and those of their competitors. 

With the rising adoption of RWD, Health Economics and Outcomes Research (HEOR) teams are able to generate and explore hypotheses around the patient journey and natural history of disease within the real world, thereby driving insights in spaces like competitive differentiation and life cycle management.

Find out how COTA Vantage can help power research to differentiate your product and inform LCM.

Why use Real-World Data?

At COTA, we curate regulatory-grade oncology RWD with the most relevance for our life sciences and provider partners, whether that involves supporting regulatory filings or research questions.  We cannot unlock the full value of RWD without the highest-quality collection and curation methodology, and we are powering a revolution in the development of new cancer therapies to bring clarity to cancer care.

 

How we define regulatory-grade data:

Provenance

  • COTA oversees the entire process from abstraction of raw data to final delivery of curated RWD
  • Traceability of all our data: where it originates, the transformations applied, and QA checks along the way

Relevance

  • The right cohorts after applying inclusion/exclusion criteria at the right volumes

  • Representativeness across real-world and clinical trial populations

  • Coverage across geographies of interest

Fidelity

  • Faithful representation of the original clinical data documented in EHR
  • Technology-enabled human abstraction leveraged to understand and capture clinical nuances
  • Accuracy of capture ensured through documented, multi-step QA/QC process
cotaIMG2

We have a responsibility to drive the use of RWD by consistently improving our data and demonstrating its utility. Our data has been used to support FDA and EMA submissions, explain care patterns, understand patient outcomes, and much more – and we anticipate the number of use cases to multiply in the coming years as RWD is explored and leveraged by more and more innovators in the industry.

Interested in learning more about how we can transform cancer care together?

RWD Resources

Getting personal with real-world data at ViVE 2024

At ViVE 2024 in Los Angeles, COTA’s Chief Medical Officer, C.K. Wang, MD will take part in a discussion session called “Data That’s Getting Personal”.

Read More

3 traits to look for in an oncology real-world data partner

Before raw, real-world data (RWD) can be transformed into actionable insights, it has to go through a number of different processes, from aggregation and abstraction to standardization and careful curation.

Read More

For the hematology community, AI and RWD are top of mind

A huge number of new breakthroughs in drug development, treatment guidelines, and decision support technologies occur every day to treat blood cancers.

Read More

Join the Conversation

Find COTA at upcoming events, and see where we’ve been.
No event found!

Past Events

06Aug

JSM 2022

Walter E. Washington Convention Center
15May

ISPOR 2022

Gaylord National Resort & Convention Center
13May

AUA 2022

New Orleans Ernest N. Morial Convention Center
No event found!
Load More

Request a Demo

  • This field is for validation purposes and should be left unchanged.

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.